Medtronic Escapes Investors' Claims Of Tainted Studies
A Minnesota federal judge on Wednesday tossed the remainder of a securities class action alleging Medtronic Inc. downplayed problems with its bone graft products and manipulated studies to drive up its...To view the full article, register now.
Already a subscriber? Click here to view full article